Compare VSTS & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VSTS | NVCR |
|---|---|---|
| Founded | 1936 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 2023 | 2015 |
| Metric | VSTS | NVCR |
|---|---|---|
| Price | $9.25 | $12.19 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 4 | 6 |
| Target Price | $5.88 | ★ $28.08 |
| AVG Volume (30 Days) | 997.5K | ★ 1.0M |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.79 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,734,839,000.00 | $655,353,000.00 |
| Revenue This Year | N/A | $7.72 |
| Revenue Next Year | $1.67 | $6.74 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 8.28 |
| 52 Week Low | $3.98 | $9.82 |
| 52 Week High | $9.80 | $20.05 |
| Indicator | VSTS | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 75.88 | 57.94 |
| Support Level | $7.24 | $10.72 |
| Resistance Level | $9.80 | $13.78 |
| Average True Range (ATR) | 0.32 | 0.59 |
| MACD | 0.15 | 0.13 |
| Stochastic Oscillator | 97.47 | 91.54 |
Vestis Corp is a provider of uniform rentals and workplace supplies across the United States and Canada. It provides uniforms, mats, towels, linens, restroom supplies, first-aid supplies, safety products, and other workplace supplies. The Company serves customers ranging from small, family-owned operations with a single location to large corporations and national franchises with multiple locations. The company operates in the United States and Canada as reportable segments. The company earns the majority of its revenue from the United States.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.